Literature DB >> 18243341

Novel roles for murine complement receptors type 1 and 2 I. Regulation of B cell survival and proliferation by CR1/2.

Eszter Molnár1, Anna Erdei, József Prechl.   

Abstract

Innate components of the immune system, such as complement are known to have a modulatory effect on adaptive immune responses. Complement receptors are expressed by both B and T lymphocytes and play part in antigen presentation and cellular activation and adhesion events. On murine B cells type 1 and 2 complement receptors (CR1/2) are expressed and form a co-receptor complex together with CD19 and CD81. We used CR1/2 specific antibodies to assess the role these receptors might play in regulating cell cycling events of B cells. We show that a CR1/2 specific antibody fragment, 7G6 scFv can induce the proliferation of mature B cells. This effect is countermodulated by FcR crosslinkage and enhanced by BCR engagement. The proliferative effect is severely impaired in Cr2-/- animals, strengthening the involvement of CR1/2. Transitional B cells are prone to apoptotic death by selection events, yet they are rescued from apoptosis by CR1/2 crosslinkage. CR1/2 ligation by 7G6 scFv alone can induce nuclear translocation of NF-kappaB, supporting the above observations. We conclude that engagement of complement receptor 2 of B cells promotes the survival of both mature and transitional B cells. This activity supplements the previously described adjuvant effects of complement.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18243341     DOI: 10.1016/j.imlet.2007.12.007

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  8 in total

1.  Developmental expression of B cell molecules in equine lymphoid tissues.

Authors:  J M B Prieto; R L Tallmadge; M J B Felippe
Journal:  Vet Immunol Immunopathol       Date:  2016-12-13       Impact factor: 2.046

Review 2.  Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology.

Authors:  Masashi Mizuno; Yasuhiro Suzuki; Yasuhiko Ito
Journal:  Clin Exp Nephrol       Date:  2017-03-24       Impact factor: 2.801

3.  A new mouse anti-mouse complement receptor type 2 and 1 (CR2/CR1) monoclonal antibody as a tool to study receptor involvement in chronic models of immune responses and disease.

Authors:  Liudmila Kulik; Finnegan B Hewitt; Van C Willis; Rosa Rodriguez; Stephen Tomlinson; V Michael Holers
Journal:  Mol Immunol       Date:  2015-02       Impact factor: 4.407

4.  C3d regulates immune checkpoint blockade and enhances antitumor immunity.

Authors:  Jeffrey L Platt; Inês Silva; Samuel J Balin; Adam R Lefferts; Evan Farkash; Ted M Ross; Michael C Carroll; Marilia Cascalho
Journal:  JCI Insight       Date:  2017-05-04

Review 5.  Why current quantitative serology is not quantitative and how systems immunology could provide solutions.

Authors:  József Prechl
Journal:  Biol Futur       Date:  2021-02-20

6.  Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model.

Authors:  Siao-Yi Wang; Suresh Veeramani; Emilian Racila; Jeffrey Cagley; David C Fritzinger; Carl-Wilhelm Vogel; William St John; George J Weiner
Journal:  Blood       Date:  2009-10-05       Impact factor: 22.113

7.  Complement anaphylatoxin C3a is a potent inducer of embryonic chick retina regeneration.

Authors:  Tracy Haynes; Agustin Luz-Madrigal; Edimara S Reis; Nancy P Echeverri Ruiz; Erika Grajales-Esquivel; Apostolia Tzekou; Panagiotis A Tsonis; John D Lambris; Katia Del Rio-Tsonis
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

8.  Spred2-deficiecy Protects Mice from Polymicrobial Septic Peritonitis by Enhancing Inflammation and Bacterial Clearance.

Authors:  Junya Itakura; Miwa Sato; Toshihiro Ito; Megumi Mino; Soichiro Fushimi; Sakuma Takahashi; Teizo Yoshimura; Akihiro Matsukawa
Journal:  Sci Rep       Date:  2017-10-09       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.